Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.
作者信息
Yuasa Takeshi
机构信息
Department of Medical Oncology and Genitourinary Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo, Japan
出版信息
Int J Urol. 2009 Sep;16(9):731-2. doi: 10.1111/j.1442-2042.2009.02367.x.
Abstract
摘要
Zotero 插件